Added to YB: 2025-07-23
Pitch date: 2025-07-21
ABVX [bullish]
ABIVAX Société Anonyme
+991.01%
current return
Author Info
No bio for this author
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
N/A
Pitch Price
EUR 8.90
Price Target
101.40 (+4%)
Dividend
N/A
EV/EBITDA
-29.07
P/E
N/A
EV/Sales
1.6K
Sector
Biotechnology
Category
special_situation
ABVX: High-Stakes UC Readout with 10x Potential and Deeply Discounted Odds
ABVX: Ulcerative colitis Ph3 readout August could bring 5-10x upside. Market pricing high failure odds despite promising data: strong maintenance efficacy (55% remission rate), Ph3 response rate tracking higher than Ph2b (53.7% vs 51.2%). Pre-disclosed enrollment data suggests 13-15% remission delta. 90%+ downside if fails. Recent UC buyouts averaged $8B vs $630M current cap.
Read full article (19 min)